Interview: Alzheimer'a[euro][TM]s disease: new paradigms for neurologists

Citation metadata

Author: Elio Scarpini
Date: Sept. 2011
From: Therapy(Vol. 8, Issue 5)
Publisher: Future Medicine Ltd.
Document Type: Column; Report
Length: 1,111 words
Lexile Measure: 1410L

Document controls

Main content

Article Preview :

Author(s): Elio Scarpini 1

* What first attracted you to a career researching Alzheimer'âs disease?

I started out studying the inflammatory mechanisms behind multiple sclerosis (MS), which is a demyelinating disease of the CNS. Considering that the ratio of patients with Alzheimer'âs disease (AD) and MS is 10:1, AD is becoming a huge health and social issue, a number of MS patients have cognitive dysfunctions and that primary progressive forms of MS show a neurodegenerative component, I started to think about possible common mechanisms between MS and AD.

Therefore, I began the analysis of cytokines, chemokines and other inflammatory factors, both in terms of levels in human samples such as CSF and serum, and genetics.

* What has been your greatest achievement to date in the field of AD?

I think the demonstration that inflammation is present and is a very early event in the pathogenesis of AD is my greatest achievement. Inflammation was first reported in the early 1980s as a crucial event responsible for the development of AD. Despite these optimistic data, treatment of AD patients with anti-inflammatory drugs failed to provide positive results. We demonstrated that inflammation does not occur during the late stages of AD, but is present exclusively in early phases, when symptoms are still very mild [1] . This explains the failure of clinical trials with anti-inflammatory drugs that were given to patients in late stages of AD when inflammation was likely not present anymore.

* Could you briefly summarize the aims & achievements of the European Neurological Society?

The main aim of the European Neurological Society (ENS) is to organize annual meetings, including both plenary sessions with experts in different areas of neurology, and...

Source Citation

Source Citation   

Gale Document Number: GALE|A268609826